Interim results from a dose-ranging Phase II trial of MK-0518(i) (n=167) showed that the oral investigational medication at all three doses studied (200 mg, 400 mg, and 600 mg orally twice daily) in combination with optimized background therapy (OBT) had greater anti-retroviral activity than placebo with OBT. Study results also showed that MK-0518 in combination with OBT was generally well tolerated in these patients with advanced HIV infection who were failing anti-retroviral therapy (ART), who had viruses resistant to at least one drug of each of the three available classes of oral ARTs and who had limited active ARTs as options for treatment. The results were presented as a late breaker yesterday at the 13th Annual Conference on Retroviruses and Opportunistic Infections (CROI).
